Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Pages (from-to)928-936
    JournalThe Lancet Oncology
    Volume16
    Issue number8
    DOIs
    Publication statusPublished - 23 Jun 2015

    Cite this